- 移动端
北京百普赛斯生物科技股份有限公司品牌商
13 年
手机商铺
商家活跃：
产品热度：
- NaN
- 0
- 0
- 2
- 2
推荐产品
公司新闻/正文
每月聚焦：PCSK9新的研究热点
965 人阅读发布时间：2015-01-07 16:23
Monthly Spotlight: PCSK9 Grabs the Headline, Again
每月聚焦：PCSK9新的研究热点
A Surprising New Role of PCSK 9 in Sepsis
PCSK9在败血症治疗中的新发现
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipoprotein homeostasis. The upregulation of PCSK9 is part of a negative feedback loop induced by widely used cholesterol lowering drug statins. Excessive PCSK9 binds to LDLR and targets LDLR for lysosomal degradation, consequently leading to an elevation of serum LDL-cholesterol level. This mechanism significantly compromises the efficacy of statins. Therefore, many pharmaceutical companies have made PCSK9 inhibitors a top priority as they compete for the multibillion dollar market of cardiovascular medicine. Both Sanofi and Regeneron’s alirocumab and Amgen’s evolocumab are pretty close to the finish line, with Pfizer’s bococizumab not too far behind.
PCSK9是维持人体脂蛋白动态平衡关键蛋白，大量使用具有降胆固醇左右的他汀类药物能够促使PCSK9过量表达。过量PCSK9结合LDLR，能够介导LDLR降解，从而导致血清LDL胆固醇水平的升高。这种机体调控机制显著降低了他汀类药物降胆固醇的功效。因此，许多制药公司针对该调控机制开发生产了PCSK9抑制剂，用以增加对胆固醇的清除作用，从而降低心血管疾病风险。赛诺菲（Sanofi）和合作伙伴再生元（Regeneron）合作开发的alirocumab、安进（Amgen）的evolocumab以及辉瑞（Pfuzer）的bococizumab是目前世界上最主要的3种在研PCSK9抑制剂药物，预计年销售峰值将达到数十亿美元或更多。
Recently PCSK9 is under the spot light again, but this time it's not about the heart. In a study published on the October issue of Science Translational Medicine, Keith Walley and colleagues from University of British Columbia uncovered a surprising new role of PCSK9 in regulating innate immune response in sepsis (Link of Article). They found that pharmaceutical inhibition of PCSK9 function helps the clearance of pathogen lipid via the LDLR, and improves septic shock outcome. Sepsis is the leading cause of death in the intensive care units. This groundbreaking discovery suggests that future PCSK9 inhibitors may also benefit millions of sepsis patients across the globe.
然而，PCSK9并不仅仅与心脑血管疾病治疗相关，还是败血症治疗方面的关键蛋白。近期，加拿大英属哥伦比亚大学Keith Walley及其同事研究发现：PCSK9在调节败血症天然免疫方面具有惊人效果。他们通过抑制或减少PCSK9的表达水平，能够帮助患者身体清除致病菌的有毒残余（抗生素抗击致病菌后所剩下的有毒物质），进而改善患者的预后和存活率。这一突破性发现为将来应用PCSK9抑制剂治疗全球败血症患者开辟了新的思路。该研究成果于2014年10月发表的Science Translational Medicine期刊上。
How Acrobiosystems PCSK9 Helped the Discovery
ACROBiosystems为PCSK9研究提供产品支持
In this study, Acrobiosystems recombinant PCSK9 (PC9-H5223) was used to treat
Immortalized human hepatocytes (HepG2 cell line, ATCC). The authors found that treatment with 3µg/ml recombinant PCSK9 (PC9-H5223) reduced LPS uptake by a staggering 65 percent in these cells.
在Keith Walley等人的研究中，ACROBiosystems公司产品PCSK9（PC9-H5223）被用于检测人肝脏细胞HepG2培养增值情况：采用3ug/ml 重组PCSK9蛋白处理HepG2细胞时，该细胞吸收LPS的能力降低65％。
Relevant Products at Acrobiosystems
相关产品
Acrobiosystems has developed a collection of PCSK9 and LDLR proteins. Our featured products include biotin labeled PCSK9, heavy labeled PCSK9, and several mutated PCSK9 proteins.
ACROBiosystems公司开发了一系列PCSK9、LDLR蛋白产品，包括生物素标记PCSK9，重元素标记PCSK9，以及突变型PCSK9等。
每月聚焦：PCSK9新的研究热点
A Surprising New Role of PCSK 9 in Sepsis
PCSK9在败血症治疗中的新发现
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipoprotein homeostasis. The upregulation of PCSK9 is part of a negative feedback loop induced by widely used cholesterol lowering drug statins. Excessive PCSK9 binds to LDLR and targets LDLR for lysosomal degradation, consequently leading to an elevation of serum LDL-cholesterol level. This mechanism significantly compromises the efficacy of statins. Therefore, many pharmaceutical companies have made PCSK9 inhibitors a top priority as they compete for the multibillion dollar market of cardiovascular medicine. Both Sanofi and Regeneron’s alirocumab and Amgen’s evolocumab are pretty close to the finish line, with Pfizer’s bococizumab not too far behind.
PCSK9是维持人体脂蛋白动态平衡关键蛋白，大量使用具有降胆固醇左右的他汀类药物能够促使PCSK9过量表达。过量PCSK9结合LDLR，能够介导LDLR降解，从而导致血清LDL胆固醇水平的升高。这种机体调控机制显著降低了他汀类药物降胆固醇的功效。因此，许多制药公司针对该调控机制开发生产了PCSK9抑制剂，用以增加对胆固醇的清除作用，从而降低心血管疾病风险。赛诺菲（Sanofi）和合作伙伴再生元（Regeneron）合作开发的alirocumab、安进（Amgen）的evolocumab以及辉瑞（Pfuzer）的bococizumab是目前世界上最主要的3种在研PCSK9抑制剂药物，预计年销售峰值将达到数十亿美元或更多。
Recently PCSK9 is under the spot light again, but this time it's not about the heart. In a study published on the October issue of Science Translational Medicine, Keith Walley and colleagues from University of British Columbia uncovered a surprising new role of PCSK9 in regulating innate immune response in sepsis (Link of Article). They found that pharmaceutical inhibition of PCSK9 function helps the clearance of pathogen lipid via the LDLR, and improves septic shock outcome. Sepsis is the leading cause of death in the intensive care units. This groundbreaking discovery suggests that future PCSK9 inhibitors may also benefit millions of sepsis patients across the globe.
然而，PCSK9并不仅仅与心脑血管疾病治疗相关，还是败血症治疗方面的关键蛋白。近期，加拿大英属哥伦比亚大学Keith Walley及其同事研究发现：PCSK9在调节败血症天然免疫方面具有惊人效果。他们通过抑制或减少PCSK9的表达水平，能够帮助患者身体清除致病菌的有毒残余（抗生素抗击致病菌后所剩下的有毒物质），进而改善患者的预后和存活率。这一突破性发现为将来应用PCSK9抑制剂治疗全球败血症患者开辟了新的思路。该研究成果于2014年10月发表的Science Translational Medicine期刊上。
How Acrobiosystems PCSK9 Helped the Discovery
ACROBiosystems为PCSK9研究提供产品支持
In this study, Acrobiosystems recombinant PCSK9 (PC9-H5223) was used to treat
Immortalized human hepatocytes (HepG2 cell line, ATCC). The authors found that treatment with 3µg/ml recombinant PCSK9 (PC9-H5223) reduced LPS uptake by a staggering 65 percent in these cells.
在Keith Walley等人的研究中，ACROBiosystems公司产品PCSK9（PC9-H5223）被用于检测人肝脏细胞HepG2培养增值情况：采用3ug/ml 重组PCSK9蛋白处理HepG2细胞时，该细胞吸收LPS的能力降低65％。
Relevant Products at Acrobiosystems
相关产品
Acrobiosystems has developed a collection of PCSK9 and LDLR proteins. Our featured products include biotin labeled PCSK9, heavy labeled PCSK9, and several mutated PCSK9 proteins.
ACROBiosystems公司开发了一系列PCSK9、LDLR蛋白产品，包括生物素标记PCSK9，重元素标记PCSK9，以及突变型PCSK9等。
| Catalog # | Product Name | Host |
Purity |
| PC9-H5223 | Human PCSK9 | HEK293 | >97% |
| PC9-H5226 | Human Mature PCSK9 (153-692) |
HEK293 | >97% |
| PCY-H5225 | Human PCSK9 (D374Y) |
HEK293 | >92% |
| PCA-H5226 | Human PCSK9 (R194A) |
HEK293 | >95% |
| PC9-H822R | Biotinylated Human PCSK9 |
HEK293 | >95% |
| PC9-H9223 | Human PCSK9 Protein, C13 and N15-labeled |
HEK293 | >97% |
| LDR-H5224 | Human LDLR |
HEK293 | >90% |
| LDR-H822R | Biotinylated Human LDLR |
HEK293 | >95% |
| LDR-H9224 | Human LDLR Protein, C13 and N15-labeled |
HEK293 | >95% |